Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411928 | 0.83 | BCAT2 (0.47) | BCAT2KDM4EALDH1A1MAPK1NOTUM | |
| SCHEMBL28988943 | 0.83 | BCAT2 (0.47) | BCAT2KDM4EALDH1A1MAPK1NOTUM | |
| SCHEMBL5878337 | 0.78 | BCAT2 (0.87) | BCAT2KDM4EALDH1A1CSNK1A1TYRO3 | |
| SCHEMBL323044 | 0.77 | NOTUM (0.55) | KDM4EALDH1A1MAPK1NOTUMMGLL | |
| SCHEMBL19794397 | 0.77 | NOTUM (0.55) | KDM4EALDH1A1MAPK1CHRM1NOTUM | |
| SCHEMBL3380448 | 0.76 | MEN1 (0.56) | BCAT2ALDH1A1MAPK1 | |
| SCHEMBL28011535 | 0.76 | PPARG (0.48) | KDM4EALDH1A1MAPK1CHRM1NOTUM | |
| SCHEMBL30582476 | 0.76 | BCAT2 (0.83) | BCAT2KDM4EALDH1A1CSNK1A1TYRO3 | |
| SCHEMBL1785239 | 0.75 | CAPN1 (0.54) | KDM4EALDH1A1MAPK1NOTUMSYK | |
| SCHEMBL3544059 | 0.75 | NPC1 (0.49) | KDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221337-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | BCAT2 3090/4885KDM4E 371/4885ALDH1A1 1360/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | BCAT2 2124/4885KDM4E 1379/4885ALDH1A1 3795/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | BCAT2 3090/4885KDM4E 371/4885ALDH1A1 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.